What is XCR Diagnostics?
XCR Diagnostics is at the forefront of molecular diagnostics, developing innovative testing solutions designed for enhanced speed and efficiency. Their proprietary Xtreme Chain Reaction technology significantly improves nucleic acid amplification, a critical step in diagnostic testing. This technological advancement aims to make diagnostic processes more streamlined and widely accessible. The company's strategic focus is on elevating healthcare quality by providing affordable, portable testing systems suitable for near-patient diagnostic applications, targeting healthcare providers and organizations that require swift and dependable infectious disease testing.
How much funding has XCR Diagnostics raised?
XCR Diagnostics has raised a total of $398K across 2 funding rounds:
Debt
$150K
Debt
$248K
Debt (2020): $150K with participation from PPP
Debt (2021): $248K led by PPP
What's next for XCR Diagnostics?
With its recent major strategic investment and substantial overall capital, XCR Diagnostics is well-positioned for its next phase of growth. The company's late-stage funding context suggests a focus on scaling operations, expanding market reach, and potentially further developing its patented Xtreme Chain Reaction technology. This infusion of capital will likely accelerate the commercialization of their diagnostic systems, enabling broader adoption in healthcare settings and reinforcing their commitment to improving diagnostic accessibility and speed for critical health concerns.
See full XCR Diagnostics company page
